Literature DB >> 15990004

Definition of elective lymphatic target volume in ductal carcinoma of the pancreatic head based on histopathologic analysis.

Thomas B Brunner1, Susanne Merkel, Gerhard G Grabenbauer, Thomas Meyer, Ulrich Baum, Thomas Papadopoulos, Rolf Sauer, Werner Hohenberger.   

Abstract

PURPOSE: In chemoradiation for pancreatic carcinoma three-dimensional target volume definitions could maximize tolerability and therapeutic effect at the same time because toxicity correlates with treatment volume. We aimed to define guidelines for elective treatment of nodal areas based on pathologic nodal involvement to optimize treatment volume for this tumor. METHODS AND MATERIALS: Pathologic patterns of regional nodal spread in 175 patients who underwent primary pancreatoduodenectomy with > or =10 assessed nodes and literature data on para-aortic spread were the base of the definition of the target volume. Significant correlations between spread to lymphatic areas and tumor characteristics were determined using Fisher's exact test. Computed tomography scans and a Pinnacle3 (Philips, Best, The Netherlands) system were used for treatment planning.
RESULTS: Among 175 resected tumors without pretreatment, 76% had regional nodal metastasis and 22% had spread to distant nodes. High-risk lymphatic areas were identified and selected for elective treatment. A standardized planning procedure was derived and tested under treatment conditions.
CONCLUSIONS: Histopathologic data allowed us to develop recommendations for standardized treatment planning for ductal carcinoma of the pancreatic head. These are proposed for quality assurance in multicenter studies and routine use.

Entities:  

Mesh:

Year:  2005        PMID: 15990004     DOI: 10.1016/j.ijrobp.2004.12.018

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  19 in total

Review 1.  [Clinical target volume : Principles and limits].

Authors:  T B Brunner; M Walke; P Hass
Journal:  Radiologe       Date:  2018-08       Impact factor: 0.635

Review 2.  Neoadjuvant therapy for potentially resectable pancreatic cancer: an emerging paradigm?

Authors:  Thomas B Brunner
Journal:  Curr Oncol Rep       Date:  2013-04       Impact factor: 5.075

3.  Volumetric modulated arc therapy for advanced pancreatic cancer.

Authors:  Wietse Eppinga; Frank Lagerwaard; Wilko Verbakel; Ben Slotman; Suresh Senan
Journal:  Strahlenther Onkol       Date:  2010-06-24       Impact factor: 3.621

Review 4.  Adjuvant chemoradiation for pancreatic cancer: what does the evidence tell us?

Authors:  Michael D Chuong; Drexell H Boggs; Kruti N Patel; William F Regine
Journal:  J Gastrointest Oncol       Date:  2014-06

5.  Radiation Therapy Oncology Group consensus panel guidelines for the delineation of the clinical target volume in the postoperative treatment of pancreatic head cancer.

Authors:  Karyn A Goodman; William F Regine; Laura A Dawson; Edgar Ben-Josef; Karin Haustermans; Walter R Bosch; Julius Turian; Ross A Abrams
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-04-05       Impact factor: 7.038

6.  Proposing the lymphatic target volume for elective radiation therapy for pancreatic cancer: a pooled analysis of clinical evidence.

Authors:  Wenjie Sun; Cheng N Leong; Zhen Zhang; Jiade J Lu
Journal:  Radiat Oncol       Date:  2010-04-15       Impact factor: 3.481

Review 7.  The role of radiotherapy in multimodal treatment of pancreatic carcinoma.

Authors:  Thomas B Brunner; Martin Scott-Brown
Journal:  Radiat Oncol       Date:  2010-07-08       Impact factor: 3.481

8.  Downstaging of pancreatic carcinoma after neoadjuvant chemoradiation.

Authors:  Dominik Tinkl; Gerhard G Grabenbauer; Henriette Golcher; Thomas Meyer; Thomas Papadopoulos; Werner Hohenberger; Rolf Sauer; Thomas B Brunner
Journal:  Strahlenther Onkol       Date:  2009-09-12       Impact factor: 3.621

9.  Comparison of four target volume definitions for pancreatic cancer. Guidelines for treatment of the lymphatics and the primary tumor.

Authors:  E Fokas; C Eccles; N Patel; K-Y Chu; S Warren; W Gillies McKenna; T B Brunner
Journal:  Strahlenther Onkol       Date:  2013-04-05       Impact factor: 3.621

10.  Adjuvant therapeutic strategies for resectable pancreatic adenocarcinoma.

Authors:  Nikhil Yegya-Raman; Mihir M Shah; Miral S Grandhi; Elizabeth Poplin; David A August; Timothy J Kennedy; Usha Malhotra; Kristen R Spencer; Darren R Carpizo; Salma K Jabbour
Journal:  Ann Pancreat Cancer       Date:  2018-08-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.